In Brief: Axcan's Urso
Executive Summary
Axcan's Urso: Ursodeoxycholic acid NDA for treatment of primary biliary cirrhosis will be reviewed by FDA's Gastrointestinal Drugs Advisory Committee at its Nov. 6-7 meeting, the company announces. The NDA was filed for the orphan indication March 25...